According to a recent study in JAMA Dermatology, AbbVie's JAK Inhibitor Rinvoq (upadacitinib) outperformed Dupixent (dupilumab) in terms of primary and secondary endpoints in a phase 3b head-to-head study involving adults with atopic dermatitis (AD). This indicates that Rinvoq may be more effective in treating this condition.